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Introduction: Controlled ovarian stimulation is an essential part of in vitro fertilization
(IVF)  cycles. The aim of this process is to permit follicular aspiration of approximately 8–
10  oocytes. Individual women have different ovarian responses based on their ovarian
reserves. Low doses of exogenous follicle-stimulating hormone (FSH) may lead to cance-
lation of an IVF cycle as a result of insufﬁcient response, and high doses may also lead to
cancelation due to the risk of ovarian hyperstimulation syndrome. Knowing the patient’s
ovarian response permits the use of individually tailored doses of gonadotropin, resulting
in  decreased occurrence of inappropriate ovarian responses.
Objective: To conduct a systematic review of antral follicle count (AFC) performance in
adjusting the dose of gonadotropins to prevent inadequate responses in IVF cycles.
Method: A systematic review was conducted of studies published in the last 13 years that
appraised AFC performance in adjusting the dose of gonadotropins to prevent inadequate
responses in IVF cycles. The databases consulted were Medline, LILACS, SciELO and Pubmed.
Search descriptors were “antral follicle count” and “ovarian hyperstimulation syndrome”.
Results: 131 articles were found. Five articles published between 2000 and 2013 were selected.
Conclusion: AFC appears to perform well in adjusting the dose of exogenous gonadotropins
to  prevent inappropriate responses in IVF cycles.©  2015 Sociedade Brasileira de Reproduc¸ão Humana. Published by Elsevier Editora Ltda.
All rights reserved. Research conduced at Infertility Clinic, Faculty of Medicine, Pontifícia Universidade Católica de Goiás (PUC-Góias), Goiânia, GO, Brazil.
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Contagem  dos  folículos  antrais  na  predic¸ão  das  doses  apropriadas  de
gonadotroﬁnas  em  ciclos  de  fertilizac¸ão  in  vitro
Palavras-chave:
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Individualizac¸ão
Síndrome da hiperestimulac¸ão
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Introduc¸ão: A estimulac¸ão ovariana controlada é parte essencial de ciclos de fertilizac¸ão
in  vitro (FIV). O objetivo deste processo é permitir a aspirac¸ão folicular de aproximada-
mente 8–10 oócitos. As mulheres têm respostas diferentes e individuais, baseadas em suas
reservas ovarianas. Baixas doses exógenas de hormônio folículo estimulante (FSH) podem
levar ao cancelamento do ciclo de FIV como resultado de resposta insuﬁciente e altas doses
também podem levar ao cancelamento devido ao risco da síndrome de hiperestimulac¸ão
ovariana. O conhecimento da resposta ovariana das pacientes permite o uso de doses indi-
viduais adaptadas de gonadotroﬁnas, resultando em diminuic¸ão da ocorrência de respostas
inadequadas do ovário.
Objetivo: Realizar revisão sistemática do desempenho da contagem dos folículos antrais
(CFA) no ajuste da dose das gonadotroﬁnas para evitar respostas inadequadas em ciclos de
FIV.
Método: Realizou-se revisão sistemática de estudos publicados nos últimos 13 anos que
avaliaram o desempenho da CFA no ajuste das doses de gonadotroﬁnas para evitar respostas
inadequadas em ciclos de FIV. As bases de dados consultadas foram Medline, LILACS, SciELO
e  Pubmed. Os descritores de pesquisa foram “contagem de folículo antral” e “Síndrome de
hiperestimulac¸ão  ovariana”.
Resultados: Foram encontrados 131 artigos. Cinco artigos publicados entre 2000 e 2013 foram
selecionados.
Conclusão: A CFA parece ter um papel importante no ajuste das doses de gonadotroﬁnas
exógenas para evitar respostas inapropriadas em ciclos de FIV.
©  2015 Sociedade Brasileira de Reproduc¸ão Humana. Publicado por Elsevier Editora
Ltda. Todos os direitos reservados.
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ontrolled ovarian stimulation is an essential part of in vitro
ertilization (IVF) cycles; the objective of this procedure is to
btain a reasonable number of oocytes that can be fertilized. In
linical practice, specialist physicians generally rely on their
xperience to select the initial dose of gonadotropins to be
sed in the cycle. There is no consensus in the literature
bout the optimal dose of follicle stimulating hormone (FSH)
n follicular stimulation to retrieve an acceptable number of
ocytes. Reports in the literature have considered the recov-
ry of 8–10 oocytes (range: 5–14) per cycle of stimulation1–3 to
e adequate.
Women differ markedly in their ovarian reserves, and
onsequently present different responses to pharmaceutical
timulation of the ovaries. The occurrence of a low response to
onadotropins may result in cancelation of the cycle. Admin-
stration of higher doses of exogenous FSH may also lead to
ancelation of the cycle due to the risk of ovarian hyperstimu-
ation syndrome (OHSS).1,4
Cytokines and high levels of vascular endothelial growth
actor (VEGF) released by the corpus luteum in the stimulated
ollicles lead to an increase in vascular permeability which is
haracteristic of OHSS.5–9 This disorder is usually self-limiting
ut may extend over a long period, mainly in cycles with
onception.6 Its incidence has increased with the expansion of
ssisted reproduction techniques.7 Mild and moderate OHSS
orms occur in 20–33% and 3–6% of all ovarian stimulationcycles, respectively, while the severe form of the syndrome
may occur in 0.1–2% of IVF cycles.4
An estimate of ovarian response is possible by ovarian
reserve tests (ORT). Among the various ORT available, the
oldest is dosage of basal FSH. Antral follicle count (AFC)
and serum levels of anti-Müllerian hormone (AMH) were
introduced more  recently.4
AFC can be used as a screening test to detect probable poor
responders, normal responders, or hyper responders, and has
the best predictive value for the number of oocytes that will
be retrieved in IVF cycles. AFC does not appear to undergo
signiﬁcant changes during a menstrual cycle, especially when
only the small antral follicles (2–6 mm)  are counted.10–13
With knowledge about the patient’s ovarian response,
individually tailored doses of gonadotropin can be used,
resulting in reduced occurrence of inappropriate ovarian
responses, fewer canceled cycles, reduced occurrence of OHSS,
performance of fewer cycles with little chance of success,
and improvements in pregnancy rates and the overall cost-
effectiveness ratio for IVF programs.4 The objective of this
study is to review the performance of antral follicle counting in
adjusting the dose of gonadotropins to prevent inappropriate
responses in IVF cycles.
MethodA systematic review was conducted of studies published
from January 2000 to December 2013 in English, Portuguese
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and Spanish. The following databases were consulted:
Medical Literature Analysis and Retrieval System Online
(MEDLINE), Literature Latin American and Caribbean
(LILACS), Scientiﬁc Electronic Library Online (SciELO), and US
National Library of Medicine (PubMed). The descriptors used
were: “antral follicle count” and “ovarian hyperstimulation
syndrome”.
Among the studies identiﬁed, prospective studies, system-
atic reviews, meta-analyses and retrospective studies that
addressed AFC as a predictor of ovarian response and individ-
ualized optimal dose of FSH to reduce inappropriate responses
in an IVF cycle were selected. Inclusion criteria were studies
with a sample composed of women <40 years of age with reg-
ular menstrual cycles, without ovarian anatomical changes
and with causes of infertility treated by assisted reproduction
techniques (ART).
The studies were selected independently and blindly by
two authors according to the inclusion and exclusion crite-
ria. Where there was disagreement between the two authors,
the opinion of a third author was employed.
One hundred and thirty-one published articles were identi-
ﬁed from the descriptors and ﬁlters used. Ninety-nine articles
were excluded by the title, by reading the abstracts, or because
of repetition in the databases, and 32 articles were selected
that related AFC as a predictor of ovarian response to individu-
alized optimal dose of FSH to reduce inappropriate responses.
From these 32 articles, three that respected the inclusion crite-
ria deﬁned for this study were selected. The reference lists of
the selected articles were analyzed to investigate the existence
of new articles addressing the topic that could be incorporated.
Two more  articles ﬁtting the proposed inclusion criteria were
included, making a total of ﬁve articles analyzed in this study.
Fig. 1 shows the ﬂowchart summarizing the strategy adopted
to identify and include the studies.
Because this study used only data published in the lit-
erature, approval by an institutional review board was not
required.
Results
Using the data from the articles, Table 1 was constructed for
comparative analysis. Four of the ﬁve articles analyzed were
prospective studies dealing with clinical trials, and one was a
case–control study with retrospective design.
The earliest study was published in 2003 by Popovic-
Todorovic et al., in Europe, while the most recent was
published by La Marca  et al., in 2013; this study was conducted
in Italy, and has the largest sample, with 505 patients. The
smaller study, with 131 women, was conducted in the UK by
Jayaprakasan et al., in 2010.
Combining the populations studied in all the articles,
1220 patients were analyzed; of these, 407 underwent con-
trolled ovarian stimulation with a ﬁxed dose of recombinant
follicle stimulating hormone (FSHr), an exogenous FSH, and
813 received individualized doses of FSHr.Discussion
The main goal of individualized treatment in IVF cycles is
to provide every patient with therapy based on their unique;2 9(3):136–142
characteristics, thereby permitting a greater chance of suc-
cess with lower risks from ovarian stimulation.14 Although
basal FSH has been used for decades, the criteria for select-
ing the appropriate initial dose of exogenous FSH have not
been fully deﬁned. The initial dose of exogenous FSH is usually
chosen according to the patient history and clinical criteria,
most important of which is the result of a prior IVF cycle.
When there is no previous cycle, in other words, when per-
forming the ﬁrst cycle in a particular patient, age, body mass
index (BMI), and markers of ovarian reserve are the principal
variables used to determine dosage.15
Older studies were not based on ovarian reserve to assist in
selecting the dose of gonadotropin used for ovarian stimula-
tion in an IVF cycle.16–19 Measurement of serum basal FSH in
women who would undergo an IVF cycle was one of the earli-
est markers of ovarian reserve to be used.20 Since the concept
of ovarian reserve was introduced, studies using AFC began to
appear. The initial studies we encountered that used AFC and
nomograms, relating the idea of FSH dose individualization
for ovarian stimulation, were the studies by Popovic-Todorovic
et al., in 2003.2,3
One of the studies proposed a nomogram for clinical use
to determine the optimal dose of FSH in an IVF cycle. This
study used a sample of women <40 years of age, without
ovarian changes, with regular menstrual cycles, and normal
serum basal FSH levels. Using a starting dose of 150 IU of FSHr,
it was possible to deﬁne the variables which could predict
ovarian response. The number of oocytes retrieved could be
predicted by AFC, total Doppler score, smoking, and level of
serum testosterone. However, the most signiﬁcant variables
in this study for predicting the number of oocytes retrieved
were AFC and ovarian volume.3
The study proposed a nomogram based on ovarian ultra-
sound parameters (AFC, ovarian volume and Power Doppler
score) and clinical data (age and smoking). The proposed opti-
mal  dose of FSHr to achieve an adequate yield of oocytes was
150 IU in 30–35-year old non-smoking women, with an aver-
age number of antral follicles, average ovarian volume, and
normal Doppler score. The optimal dose of FSHr proposed in
the study was 100 IU in a non-smoking woman <30 years of age
with large ovaries, many  antral follicles, and a high Doppler
score. A dose of 250 IU was more  appropriate in the study for
a smoking woman >35 years of age with few antral follicles,
small ovaries, and a low Doppler score. During assembly of
the nomogram,  3 cases of OHSS were observed when the ini-
tial dose of 150 IU of FSHr was used. The study did not report
any cases of cancelation of the IVF cycle as a result of poor
ovarian response (less than 5 oocytes retrieved).3
In 2003, Popovic-Todorovic et al. used the nomogram in a
randomized, double-blind prospective clinical trial to evalu-
ate the results of using an dose of FSH of between 100 and
250 IU/day. The sample was divided into a control group or
standard dose (150 IU) and an experimental group or individ-
ualized dose. There was a signiﬁcant difference in outcome
between the groups: in the experimental group, 77.1% of
women had an adequate response to ovarian stimulation
(deﬁned as 5–14 oocytes retrieved) compared with 65.6% in
the control group.2
Furthermore, the study showed that lower doses of FSH
in patients with low ovarian reserve generated inappropriate
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Table 1 – Summary of data found in the systematic review.
Author Year Place Type of study N  Dose of FSH (IU) Mean of
retrieved oocytes
Pregnance rate
(%)
Severe OHSS Insufﬁcient
response
Predictive
variables of
ovarian response
Popovic-
Todorovic
et al.
2003 Denmark Clinical trial
(Prospective)
145  150 9.50 28.30 3.00 (4.3%) Not informed AFC, ovarian
volume, Power
Doppler grade,
age, smoking
Popovic-
Todorovic
et al.
2003 Denmark Clinical trial
(Prospective)
267  150/individualized
base on
nomogram
10.1/11.3 35.90/45.00 4.00 (5.2%)/1.00
(1.3%)
14.00
(10.7%)/2.00
(1.5%)
AFC,  ovarian
volume, Power
Doppler grade,
age, smoking
Olivennes
et al.
2009 Multicentric
(Latin America,
Europe and Asia)
Clinical trial
(Prospective)
172  Nomogram 9.00 34.20 2.00 (3.4%) 23.00 (13.3%) Age, BMI, basal
FSH, AFC
Japrayakasan
et al.
2010 United Kingdom Clinical trial
(Prospective)
131  300/225 8.20/9.00 31.00/41.00 Zero (0%)/1.00
(1.5%)
Zero (0%)/4.00
(6.1%)
AFC
La Marca
et al.
2013 Italy Case control
(Retrospective)
505  Nomogram 9.20 Not informed Zero (0%) 16.00 (3.2%) AFC, age, serum
FSH
FSH, follicle-stimulating hormone; IU, international unit; OHSS, ovarian hyperstimulation syndrome; AFC, antral follicle count; BMI, body mass index.
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32 articles selected, evaluated, 
and analyzed in full 
Inclusion criteria
Age < 40 years
Regular menstrual cycles
No ovarian anatomical 
changes 
Causes of infertility treatable 
by ART 
Identification of articles 131 and 
reading summaries
Inclusion of 3 articles
Review the list of references
Eletronic Databases
Medline, LILACS, SciELO e 
PubMed
Descriptors
Antral follicle count
Ovarian hyperstimulation 
syndrome 
Filters
Languages: english, 
portuguese, and spanish
Period: January 2000 to 
December 2013Inclusion criteria
CFA as a predictor of 
ovarian response and the 
ideal dose of FSH for 
reducing inadequate 
response
Inclusion of 2 articles
Total of 5 studies 
included
Popovic et al. 2003a
Popovic et al. 2003b
La Marca et al. 2013
Olivennes et al. 2009
Jayprakasan et al. 2010
logyFigure 1 – Flowchart of the methodo
responses, increasing rates of IVF cancelation. In the group
receiving the individualized dose of FSHr, 1.5% of the cases
were canceled due to insufﬁcient ovarian response; in the
ﬁxed-dose group, cancelation was noted in 10.7% of cases.
It was also observed that patients undergoing individualized
doses of FSHr did not require gonadotropin dosage adjust-
ments, and also presented fewer cases of OHSS, suggesting
that each patient has an optimal dose.2
In 2009 a more  marked tendency to individualize doses of
exogenous FSH began to appear. The Consort study applied
the Consort algorithm for individualized dosing of exogenous
FSHr in normo-ovulatory women aged 18–34 years. The algo-
rithm considered four parameters from the literature: age,
BMI, basal FSH, and AFC, assigning increments of 37.5 IU of
FSHr according to these characteristics. This study supported
studies showing that hormonal assessments such as the lev-
els of inhibin B, anti-Müllerian hormone (AMH), and FSH may
add to but not replace AFC, which seems to be more  valuable
for evaluating follicular reserve.1,3
This study suggested that low doses of gonadotropins are
associated with higher incidence of canceled IVF cycles and
consequent failure to retrieve oocytes. The study presented
fewer cases of OHSS when compared with studies in which
ﬁxed-doses of FSHr are used, as seen in the study by Popovic-
Todorovic et al. (2003). The results corroborate the importance
of individualizing the dose of exogenous FSH used in assisted
reproduction.1,3
In 2010, Jayaprakasan et al. used AFC as a predictor of
ovarian response to compare ﬁxed doses of gonadotropins employed in the systematic review.
(225 and 300 IU) and did not observe a signiﬁcant difference in
the number of oocytes retrieved in women undergoing these
doses during an IVF cycle, corroborating the studies of Henk
et al., and the Latin-America and Puregon IVF Study Group
report that compared the inﬂuence of ﬁxed doses of 150 IU
and 250 IU of FSHr in the number of retrieved oocytes.
These studies also did not show a signiﬁcant difference
in the number of oocytes retrieved when comparing doses of
150 IU and 250 IU. These doses did not exhibit signiﬁcant dif-
ferences in the number of OHSS cases reported. In the study
by Jayaprakasan et al., 6.1% of cycles were canceled because
of insufﬁcient response in the group that received 225 IU of
FSHr, while no cancelation was observed in the group receiving
300 IU of FSHr.1,3,16,17,21,22
In 2013, the retrospective study by La Marca  et al. aimed
to develop a nomogram based on age and markers of ovarian
reserve to calculate the appropriate starting dose of exogenous
FSH to be applied in IVF cycles in order to reduce the extremes
of ovarian response. The analysis showed that the number
of oocytes retrieved was predicted by age, BMI, smoking sta-
tus, serum basal FSH, and AFC, but statistical signiﬁcance was
achieved only by age, basal FSH, and AFC. These predictors
were used to construct the nomogram which can be easily
used in clinical practice.
The study conﬁrmed that ovarian response to FSH dose
depends primarily on ovarian reserve. Moreover, it shows that
individualizing the dose of gonadotropin used in ovarian stim-
ulation reduces the number of cases of inadequate ovarian
response. No cases of OHSS were reported in the study, and
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t was observed that only 3.2% of cases were canceled due to
nsufﬁcient ovarian response.15 It was seen that in the stud-
es using individualized doses of exogenous FSH, rates of cycle
ancelation as a result of insufﬁcient response are lower.
In addition to the study by La Marca  et al., the stud-
es by Popovic-Todorovic et al., CONSORT, and Ocal et al.
emonstrate the signiﬁcance of AFC as a predictor of ovarian
esponse.23–25 The same concept is supported by the Optimist
012 study proposal. The objective of this study is to perform
wo tests, one with poor responders and one with hyper-
esponders, sorted by AFC. The expectation of this proposal is
n increase of 30–41% in the rate of live births after adjusting
he dose of FSH; the study will also integrate the results into
 decision model to compare the cost-effectiveness of three
trategies for adjusting the dose of exogenous FSH.1–4,15,22,25
onclusion
ven with the small number of articles, this review highlights
he fact that AFC appears to perform well in adjusting the
ose of exogenous gonadotropins to prevent inappropriate
esponses in IVF cycles. Initial studies tended to use a standard
ose of exogenous FSH. Current studies about ovarian reserve
nd AFC show a tendency to apply individualized doses of
xogenous gonadotropins. The use of nomograms  containing
FC may assist in clinical practice. Further studies are now
eing conducted to evaluate the potential of AFC in preven-
ing hyperstimulation syndrome and inadequate responses in
n vitro fertilization cycles.
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